AVAH
Aveanna Healthcare Holdings Inc
$12.86
▲ 1.5%Updated Today 11:10 AM ET
AVAH at a glance — five pillars scored 0–100 from real filed financials.
Overall: Unrated · 0/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
Market Cap
$0.00
P/E
—
Forward P/E (est.)
—
ROE
—
Revenue Growth
—
EPS Growth
—
Profit Margin
—
FCF Yield
—
Debt / Equity
—
ROIC
13.0%
Interest Coverage
1.83x
Current Ratio
1.16x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
0/100
Aveanna Healthcare Holdings Inc (AVAH) is a small-cap company in the Health Care industry, part of the Health Care sector of the S&P 500.
In its latest reported year it generated about $2.43B in revenue and $225.03M in net profit.
Our model rates AVAH Unrated (0/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Evidence of durable competitive advantage in the filed financials (6 years of history).
Some durable-advantage evidence, but not across the board — dig into which ingredient is weak and whether it's cyclical or structural.
32.0% average over the last 3 years
±1.0 pts around 31.3% across 6 years
grew in 5 of the last 5 year-over-year periods
positive in 4 of 6 years
13.0% latest fiscal year
A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.
4Y CAGR
12.9%
Revenue moved from $1.38B in 2019 to $2.43B in 2026, a 11.9% compound annual growth rate. The most recent year was roughly steady year over year. Slower, mature growth is common for established businesses.
Gross Margin
33.3%
Operating Margin
10.5%
Net Margin
9.2%
ROE
—
Total Debt
$1.30B
Net Debt
$1.20B
Net Debt / EBITDA
4.68x
Debt / Equity
—
Leverage: debt-to-equity is n/a, and operating profit covers interest about 1.8x, with a current ratio of 1.2x. Detailed balance-sheet leverage is limited for this name. It carries roughly $1.30B of total debt against $97.20M of cash.
Operating CF
$125.86M
Free Cash Flow
$125.86M
FCF Margin
5.2%
In the latest year Aveanna Healthcare Holdings Inc produced about $125.86M of operating cash flow and $125.86M of free cash flow after capital spending. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
—
P/S
—
P/B
—
EV / EBITDA
—
AVAH trades at n/a trailing earnings. With no positive trailing earnings, value it on sales, cash flow, or growth rather than P/E.
Where AVAH sits versus its Health Care sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How AVAH stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (324 S&P 500 companies), AVAH ranks #115 of 324 by our overall rating.
P/E vs sector
—
median 27.3x
ROE vs sector
—
median 14.1%
Growth vs sector
—
median 7.6%
Sector rank
#115
of 324 by rating
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 324 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $12.86 today · expected CAGR 7% – 18%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $2.63B | $2.84B | $3.07B | $3.31B | $3.58B |
| Net income | $236.51M | $255.43M | $275.86M | $297.93M | $321.77M |
| EPS | $1.08 | $1.17 | $1.26 | $1.37 | $1.47 |
| Share price (low) | $13.01 | $14.05 | $15.17 | $16.38 | $17.69 |
| Share price (high) | $21.68 | $23.41 | $25.28 | $27.31 | $29.49 |
| CAGR (low–high) | 1% / 69% | 5% / 35% | 6% / 25% | 6% / 21% | 7% / 18% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for AVAH:
- As an established S&P 500 member in Health Care, it brings scale and a long operating history.
The case against AVAH:
- Interest coverage is thin (1.8x), so debt costs bite.
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Aveanna Healthcare Holdings Inc is a small-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at n/a earnings, which our model scores Unrated (0/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 17 Wall Street analysts covering AVAH recommend (August 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Analysts have turned more positive over the last three months (+12 pts of buy ratings).
Latest SEC Filings
AVAH's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
AVAH — frequently asked questions
Is AVAH a good stock to buy?
We don't give buy or sell advice. Review Aveanna Healthcare Holdings Inc's fundamentals, valuation, and 5-year financials on this page, then make your own decision — and consider a licensed professional.
Where does AVAH's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Aveanna Healthcare Holdings Inc's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for AVAH calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this AVAH analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell AVAH. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.